

## Supplementary Material 1

Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Thiocolchicoside containing Medicinal Products for Systemic Use in France, Greece, Italy and Portugal

### **Web questionnaire**

#### **Physician Demographics and practice information**

##### **D1 Respondents age category**

**D1.** What is your age category?

≤ 30 years old	( )
31-39 years old	( )
40-49 years old	( )
50-59 years old	( )
≥ 60 years old	( )

*Data: single punch*

##### **D2 Years in medicine practice**

**D2.** Years in medicine practice

≤1 year	( )
1-5 years	( )
>5-10 years	( )
>10 years	( )

*Data: Single punch*

##### **D3 Main specialty**

**D3.** What is your main medical specialty?

General practice (GP)/family physician	( )
Rheumatology	( )
Orthopedy	( )
Other, please specify:.....	( )
None of the above	

*Data: single punch*

*Data: list of physicians' specialties.*

*Data: If "None of the above", screen out*

**D3a Years in main specialty**

**D3a.** For how long have you been working in this specialty?

since which date: |\_|\_|/|\_|\_|\_|\_| (month/ year)

**OR** for |\_|\_| years

*Data: open numeric*

*Data: If response in years, this cannot exceed answer in D2*

*Data: Mandatory to enter either a date or number of years*

**D4 Setting majority of time**

**D4.** In which type of setting do you work the majority of your time?

Office based	( ) <b>Go to Screener</b>
Hospital based	( ) <i>Go to question D5</i>
Both, office and hospital	( ) <i>Go to question D5</i>

*Data: single punch*

**D5 Type of setting**

**D5.** Type of setting (tick all that are applicable).

Primary care	( )
Secondary care	( )
Specialty care outpatient	( )
Hospital/Community care	( )

*Data: Multi punch*

## Screener

### **S1 Prescription of systemic TCC last 12 months**

**S1.** Have you prescribed systemic thiocolchicoside containing medicinal products in the last 12 months?

Yes	( ) <i>Continue</i>
No	( ) <i>End of questionnaire</i>

*Data: single punch*

-----  
--

### ***Questions for the physicians who have prescribed systemic thiocolchicoside containing medicinal products within the last 12 months (=passing screener)***

#### **S1a No of TCC prescriptions last 12 months**

**S1a.** Please estimate the number of prescriptions (not patients) of systemic (oral and/or intramuscular) systemic thiocolchicoside containing medicinal products that you have written within the last 12 months.

....
.....
....

*Data: Open numeric 1-1000*  
*If <1, screen out*

**Section 1: Prescribing conditions and safety information/warnings of thicolchicoside containing medicinal products for systemic use**

**Explanatory text**

Please answer the following general questions about the prescribing conditions and safety information of systemic thicolchicoside containing medicinal products.

**Q0 Awareness of TCCleaflet changes**

**Q0.** Are you aware of any changes made to package leaflet of thicolchicoside containing medicinal products in the last 3 years?

Yes	( )
No	( )

Data: single punch

**Q1 TCC indication**

**Q1.** What is the exact indication of systemic thicolchicoside containing medicinal products among the following?

(Only one answer is correct)

Indications	
Common low back pain	( )
Adjuvant treatment of painful muscle contracture in acute spinal pathology in adults and adolescents from 16 years onwards	( )
Chronic or long term painful muscle contractures conditions	( )
Acute painful muscle contractures conditions	( )
I do not know	( )

Data: Single punch

Data: randomize order of indications situations

**Q2 TCC contraindication**

**Q2.** In which patients are systemic thicolchicoside containing medicinal products contraindicated and **should not** be prescribed to?

Several options can be chosen.

*Information text for internal/ analysis use only – not to be translated, not to be included in programming: (answer: thicolchicoside is contraindicated and must not be used: in patients hypersensitive to the active substance or to any of the excipients, during the entire pregnancy period, ducting lactation, in women of childbearing potential not using contraception)*

Patient's status	
Patients hypersensitive to thicolchicoside active substance or excipients	( )
Children and adolescents under 16 years old	( )
Males	( )
Women of childbearing potential not using contraception	( )
Pregnant women	( )
Breastfeeding women	( )
I do not know	( )

Data: Multi punch  
Data: Single punch if 'I do not know' is ticked

**Q3 TCC dosage**

**Q3.** Which of the following options regarding the recommended maximal dose and duration of use of systemic thiocolchicoside containing medicinal products are correct?

(Only one answer is correct for each form)

*Information text for internal/ analysis use only – not to be translated, not to be included in programming: (answer: thiocolchicoside should be restricted as recommended. Dose and duration should not exceed:*

- Oral forms: 8 mg every 12 hours: 16 mg/day, limited to 7 consecutive days.
- IM forms: 4 mg every 12 hours: 8 mg/day, limited to 5 consecutive days.

*It is not to be used for Long term use of chronic conditions).*

<b>Oral form: methods of administration, dose and posology</b>	
8 mg/day (4 mg every 12 hours) and no limited treatment duration	( )
16 mg/day (8 mg every 12 hours) and no limited treatment duration	( )
16 mg/day (8 mg every 12 hours) and limited to 7 consecutive days	( )
I do not know	( )

<b>Intramuscular form: methods of administration, dose and posology</b>	
8 mg/day (4 mg every 12 hours) and no limited treatment duration	( )
8 mg/day (4 mg every 12 hours) and limited to 5 consecutive days	( )
16 mg/day (8 mg every 12 hours) and limited to 7 consecutive days	( )
I do not know	( )

Data: Multi punch  
Data: randomize order of situations  
Data: One response per table mandatory. Show both tables on the same page under the question, but clearly separated as "Oral" and "Intramuscular"

**Q4 Patient information provided**

**Q4.** Which information would you communicate to your patient before prescribing systemic thiocolchicoside containing medicinal product?

Please try to answer using key words.

*Information text for internal/ analysis use only – not to be translated, not to be included in programming: (answer: inform about the risks of potential infertility associated with thiocolchicoside. One product formed in the body has shown to cause damage to some cells (abnormal number of chromosomes) in animals and in cell laboratory studies. In humans, this type of damage to cells is a risk factor for harm to the unborn child and impairment of male fertility and a potential risk factor for cancer)*

Please specify:

.....

.....

.....

.....

.....

Data: Open text, to be coded

**Q5 Advice to women in childbearing years**

**Q5.** What would you specifically advise to a women of childbearing potential if they need to be prescribed with systemic thicolchicoside containing medicinal products?

*Please try to answer using key words.*

*Information text for internal/ analysis use only – not to be translated, not to be included in programming: (answer: inform about the risks associated with thicolchicoside during pregnancy; need to use effective contraception; need to rapidly consult if the female patient becomes pregnant or is planning a pregnancy)*

<p><i>Please specify.</i></p> <p>.....</p> <p>.....</p> <p>.....</p> <p>.....</p> <p>.....</p>
--

*Data: Open text, to be coded*

**Section 2: Awareness of and attitude towards the latest prescribing conditions and safety information of thiocolchicoside for systemic use**

**Q1\_1 Sources of safety information**

**Q1\_1.** Which of the following sources have provided you the latest safety information regarding systemic thiocolchicoside containing medicinal products since *[to be adapted to the country, e.g. February 2014 for Portugal]* ?

Direct Healthcare Professional Communication (DHPC) (a letter communicating important prescribing conditions and safety information)	( )
Educational Materials (EM) (documents designed for the patient and the physician)	( )
Summary of Product Characteristics (Label)	( )
National Health Authority website	( )
Pharmaceutical company website	( )
Medical / Pharmaceutical representatives	( )
Congress / symposia	( )
Colleagues	( )
Drugs dictionary	( )
Press / media	( )
Do not know/recall the source	
Other(s), please specify: .....	( )

Data: Multi punch

Data: Randomize the order, with an exception for "Don't know" and "Other" – always keep these as the last options

**Translation/ QC: Update Q1\_1, Q2\_2a and q2\_2b according to the below table:**

	<b>France</b>	<b>Greece</b>	<b>Italy</b>	<b>Portugal</b>
<b>Distribution of DHPC</b>	April 2014	February 2014	February 2014	February 2014
<b>Distribution of EM</b>	April 2016	December 2015	October 2015	September 2015

**Q2\_2a DHPC date**

**Q2\_2a.** Have you received the Direct Healthcare Professional Communication (DHPC) related to systemic thiocolchicoside containing medicinal products since *[to be adapted to the country, e.g. February 2014 for Portugal]*?

Yes	( )
No	( )

Data: Single punch

**Q2\_2b EM date**

**Q2\_2b.** Have you become aware about/received any Educational Materials (EM) related to systemic thiocolchicoside containing medicinal products since *[to be adapted to the country, e.g. February 2014 for Portugal]*?

Yes	( )
No	( )

*Data: Single punch*

**Q3\_3 Perceived usefulness of DHCP EM**

**Q3\_3.** Do you find that the DHCP / educational materials concerning systemic thiocolchicoside containing medicinal products are appropriate / usefull

For prescribing	
- Yes	( )
- No	( )
For advising the patient	
- Yes	( )
- No	( )

*Data: Single punch per table section; one response per section mandatory*

*Data: Show both table sections ("For prescribing" and "For advising") on the same page under the question, but clearly separated*



### **Section 3: Information about recent prescriptions**

#### ***Explanatory text***

Please try to recall the last prescriptions of **systemic thiocolchicoside** containing medicinal products (oral or injected forms) you wrote to patients in the last 12 months.

Please begin from the latest prescription and fill-in the details for up to the last **5** prescriptions you have written, as detailed as possible and preferably without any omission. Please complete this section with the requested patient information based on your recall. Be assured that all patient data requested is fully anonymous and will be collated with data provided by other respondents' and presented to the sponsor in an aggregated and fully anonymised form.

As per the 2011 EphMRA (European Pharmaceutical Market Research Association) code of conduct this information is being collected for this survey purposes only.

*Data: Repeat P1-P11 for up to 5 patients.*

#### **P1 Date of prescription Month and Year**

**P1.** Please provide the approximate date of the prescription:

Month (MM) |\_\_|\_\_| Year (YYYY) |\_\_|\_\_|\_\_|\_\_|

I do not recall

*Data: Open numeric month 1-12, year 2015-2016*

#### **P2 Patients age**

**P2.** Please provide the approximate patient's age at the time of prescription:

<16 years old

≥16 years old

*Data: Single punch*

#### **P3 Patients gender**

**P3.** Patient's gender:

Male

Female

*Data: Single punch*

#### **P3a Patients contraceptive status**

**P3a.** If the patient is a female of childbearing potential(≥13 and <49 years), please specify if at the time of prescription:

1. She was using an effective method of contraception

2. She was not using effective methods of contraception

3. She was not pregnant

4. She was pregnant (or thought to be pregnant)

5. She was planning to become pregnant

6. She was breastfeeding

7. I did not ask if she was pregnant

8. I did not ask if she was using an adequate contraception

- 9.I do not recall

*Data: Multiple punch*

*Data: Single punch if 'I do not recall' - option 9 - is ticked*

*Data: Not possible to combine option 1 and 2, option 3 and 4, option 4 and 5, 4 and 6*

*Do not show figures connected to the statements, they are only for internal use*

**P4 Indication**

**P4.** For which indication did you prescribe systemic thicolchicoside containing medicinal product at the time of prescription:

- As treatment of painful muscle contractures not related to any spinal pathology
- As adjuvant treatment of painful muscle contractures in acute spinal pathology in adults and in adolescents from 16 years onwards
- Other, please specify.....
- I do not recall

*Data: Single punch*

**P5 Admin form and dosage**

**P5.** Which form and daily dose of systemic thicolchicoside containing medicinal product did you write at the time of prescription:

Oral thicolchicoside	
Intra-muscular (IM) thicolchicoside	
I do not recall	

|\_|\_| mg, \_\_\_\_\_ times per day: |\_|\_| mg as total daily dose for |\_|\_| days

- I do not recall

*Data: Single punch for table with administration form*

*Data: Open numeric 0-100 for mg dose and times /day*

*Show table with admin forms and daily dose on same page. If respondent ticks "Don't know" for admin form, skip daily dosage open numerics*

**Supplementary Material 2**

Tables reporting the physician gender, specialties and level of experience sorted by countries and in total, for participating and non-participating physicians.

**TOTAL**

Variables		Participants	Non participants
Gender	F	26,11%	34,65%
	M	73,89%	65,35%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
Specialty	GP	52,53%	80,66%
	Rheumatologists	22,27%	4,59%
	Orthopedists	25,19%	14,75%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
License year (average)		1991	1988

**Portugal**

Variables		Participants	Non participants
Gender	F	43,55%	54,25%
	M	56,45%	45,75%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
Specialty	GP	66,13%	88,70%
	Rheumatologists	16,94%	1,56%
	Orthopedists	16,94%	9,74%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
License year (average)		1994	1990

**Italy**

Variables		Participants	Non participants
Gender	F	15,76%	31,10%
	M	84,24%	68,90%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
Specialty	GP	42,08%	80,40%
	Rheumatologists	19,00%	4,28%
	Orthopedists	38,91%	15,32%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
License year (average)		1988	1987

**France**

Variables		Participants	Non participants
Gender	F	29,15%	35,98%
	M	70,85%	64,02%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
Specialty	GP	52,50%	78,26%
	Rheumatologists	25,50%	7,09%
	Orthopedists	22,00%	14,65%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
License year (average)		1992	1988

**Greece**

Variables		Participants	Non participants
Gender	F	19,81%	29,88%
	M	80,19%	70,12%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
Specialty	GP	50,00%	81,39%
	Rheumatologists	25,00%	1,99%
	Orthopedists	25,00%	16,62%
	<i>Total</i>	<i>100%</i>	<i>100%</i>
License year (average)		1997	2002